Sight Sciences, Inc. (NASDAQ: SGHT) is a publicly traded ophthalmic medical device company focused on developing transformative, interventional technologies to elevate the standard of care for eye diseases. Founded in 2011 by Paul Badawi and his brother David Badawi, the company is headquartered in Menlo Park, California, and operates with ...Sight Sciences, Inc. (NASDAQ: SGHT) is a publicly traded ophthalmic medical device company focused on developing transformative, interventional technologies to elevate the standard of care for eye diseases. Founded in 2011 by Paul Badawi and his brother David Badawi, the company is headquartered in Menlo Park, California, and operates with approximately 186 employees. The company's mission is to provide eyecare providers with clinically proven, intuitive, and less invasive therapies, shifting the treatment paradigm from chronic disease management to early intervention.
Sight Sciences' product portfolio includes two primary offerings. The OMNI Surgical System is a surgical device used by ophthalmologists to reduce intraocular pressure in adult glaucoma patients, targeting the three main points of aqueous humor outflow resistance. The TearCare System is a non-surgical, wearable eyelid technology used to manage dry eye disease (DED). These products are marketed across the United States through a direct sales force and distribution partners, reaching hospitals, medical centers, and eye care professionals.
Financially, Sight Sciences is in a growth phase. In the trailing twelve months (TTM), the company reported a market capitalization of approximately $427 million, with a price-to-sales ratio of 5.12. The company has not yet achieved profitability, with a net profit margin of -35.7% TTM, reflecting significant investment in sales, general, and administrative activities (SG&A-to-revenue ratio of 108.4%) and research and development (R&D-to-revenue ratio of 13%). However, the company maintains a strong balance sheet with a current ratio of 4.95 and a cash ratio of 3.89, indicating substantial liquidity. The gross profit margin is high at 88%, underscoring the favorable economics of its medical devices. The company’s operating cash flow is negative, but its capital expenditure is low, allowing it to manage cash burn effectively.
Key leadership includes founder and CEO Paul Badawi, who also serves as a co-inventor of the OMNI system. The company has strengthened its board with appointments like Gary Burbach, reflecting its commitment to governance. Since its IPO in July 2021, Sight Sciences has focused on commercial expansion, clinical evidence generation, and product innovation. With over 300,000 procedures performed worldwide using its technologies, the company is poised to continue its mission of reimagining eyecare through interventional approaches. Future directions include expanding indications, enhancing product features, and potentially capturing a larger share of the glaucoma and dry eye disease markets.
Operator: Good day and thank you for standing by. Welcome to the Sight Sciences Second Quarter 2026 Earnings Results Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to Trip Taylor with Investor Relations. Please go ahead.
Philip Taylor: Thank you for participating in today's call. Presenting today are Sight Sciences' Co-Founder and Chief Executive Officer, Paul Badawi, and Chief Financial Officer, Jim Rodberg. Also in attendance is Sight Sciences Chief Operating Officer, Ali Bauerlein. Earlier today, Sight Sciences released financial results for the second quarter ended June 30, 2026, and raised its revenue guidance and lowered its adjusted operating expense guidance for full year 2026. A copy of the press release is available on our website at investors.sightsciences.com. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements, including statements about our projected financial results, including revenue and adjusted operating expenses, our product development plans, market acceptance of our products, changes in the reimbursement environment, and our ability to drive profitability and achieve cash flow breakeven. These statements are based on plans and expectations as of today, which may change over time. In addition, actual results could differ materially from projected results due to a number of risks and uncertainties. For discussion of factors that may affect the company's future financial results and business, please refer to the earnings release issued prior to this call in the company's most recent SEC filings. We undertake no obligation to publicly update or revise any forward-looking statements, except as required by law. Also on this call, management refers to certain financial measures that were not prepared in accordance with generally accepted accounting principles in the United States, including adjusted operating expenses. We believe these non-GAAP financial measures are important indicators of the company's operating performance because they exclude items that are unrelated to and may not be indicative of its core operating results. See our earnings release for a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures, as well as additional information about our reliance on non-GAAP financial measures. I will now turn the call over to Paul.
Paul Badawi: Thanks, Trip. Good afternoon, and thank you for joining us. We delivered a strong second quarter, with revenue growing 20% year over year, our highest growth rate since 2023, and our second consecutive quarter of double-digit growth. This performance reflected growth in both segments, with Interventional Dry Eye achieving record revenue as TearCare adoption scaled in the reimbursed market, and Interventional Glaucoma delivering its highest year-over-year growth …
